Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels
- 1 July 2011
- journal article
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 18 (7), 997-998
- https://doi.org/10.1016/j.jocn.2010.12.011
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science (19209032, 20390241)
- Ministry of Education, Culture, Sports, Science and Technology
- National Institute of Neurological Disorders and Stroke (K-23 NS0-48869)
- Ministry of Health, Labour and Welfare
- Genentech
This publication has 7 references indexed in Scilit:
- Intrathecal pathogenic anti–aquaporin‐4 antibodies in early neuromyelitis opticaAnnals of Neurology, 2009
- Rituximab Mediates a Strong Elevation of B-Cell-Activating Factor Associated with Increased Pathogen-Specific IgG but Not Autoantibodies in Pemphigus VulgarisJournal of Investigative Dermatology, 2009
- Treatment of Neuromyelitis Optica With RituximabArchives of Neurology, 2008
- Antibody to aquaporin-4 in the long-term course of neuromyelitis opticaBrain, 2008
- Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titreBrain, 2007
- IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channelThe Journal of Experimental Medicine, 2005
- TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune diseaseNature, 2000